127 related articles for article (PubMed ID: 9057086)
1. Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase II inhibitors with different mechanisms of action.
Pérez C; Vilaboa NE; García-Bermejo L; de Blas E; Creighton AM; Aller P
J Cell Sci; 1997 Feb; 110 ( Pt 3)():337-43. PubMed ID: 9057086
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
5. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis.
Nip J; Strom DK; Fee BE; Zambetti G; Cleveland JL; Hiebert SW
Mol Cell Biol; 1997 Mar; 17(3):1049-56. PubMed ID: 9032231
[TBL] [Abstract][Full Text] [Related]
6. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
7. Etoposide-induced differentiation of U937 promonocytic cells: AP-1-dependent gene expression and protein kinase C activation.
Pérez C; Vilaboa NE; Aller P
Cell Growth Differ; 1994 Sep; 5(9):949-55. PubMed ID: 7819132
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling of apoptosis and Jun/AP-1 activity in human promonocytic cells treated with DNA-damaging and stress-inducing agents.
Galán A; Garcia-Bermejo L; Vilaboa NE; de Blas E; Aller P
Eur J Cell Biol; 2000 Jan; 79(1):1-9. PubMed ID: 10711420
[TBL] [Abstract][Full Text] [Related]
9. cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells.
García-Bermejo L; Pérez C; Vilaboa NE; de Blas E; Aller P
J Cell Sci; 1998 Mar; 111 ( Pt 5)():637-44. PubMed ID: 9454737
[TBL] [Abstract][Full Text] [Related]
10. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
11. ICRF-193 modifies etoposide-induced apoptosis in thymocytes.
Tanimoto C; Hirakawa S; Kawasaki H; Hayakawa N; Ota Z
Acta Med Okayama; 1995 Dec; 49(6):281-6. PubMed ID: 8770236
[TBL] [Abstract][Full Text] [Related]
12. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
Jensen LH; Nitiss KC; Rose A; Dong J; Zhou J; Hu T; Osheroff N; Jensen PB; Sehested M; Nitiss JL
J Biol Chem; 2000 Jan; 275(3):2137-46. PubMed ID: 10636919
[TBL] [Abstract][Full Text] [Related]
14. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
15. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
Niitsu N; Higashihara M; Honma Y
Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
[TBL] [Abstract][Full Text] [Related]
16. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
17. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
18. Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells.
Fattman CL; Allan WP; Hasinoff BB; Yalowich JC
Biochem Pharmacol; 1996 Aug; 52(4):635-42. PubMed ID: 8759037
[TBL] [Abstract][Full Text] [Related]
19. Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange.
Hamatake M; Andoh T; Ishida R
Anticancer Drugs; 1997 Jul; 8(6):637-42. PubMed ID: 9300580
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
